John P Greer

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations
    J Stuart Salmon
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Clin Lymphoma Myeloma 6:273-80. 2006
  2. ncbi Natural killer-cell neoplasms
    John P Greer
    Hematology Stem Cell Transplantation, 1301 Medical Center Drive, 2665 TVC, Nashville, TN 37232, USA
    Curr Hematol Malig Rep 4:245-52. 2009
  3. ncbi FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy
    William C Lavely
    Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232 2675, USA
    Int J Radiat Oncol Biol Phys 57:307-15. 2003
  4. ncbi Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP)
    Madan H Jagasia
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5505, USA
    Biol Blood Marrow Transplant 15:1288-95. 2009
  5. ncbi Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification
    Edward R Arrowsmith
    Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5505, USA
    Leuk Lymphoma 44:241-9. 2003
  6. ncbi Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series
    Beth L Brogan
    Departments of Medicine, Vanderbilt University Medical School, Nashville, Tennessee 37232-5227, USA
    J Am Acad Dermatol 49:223-8. 2003
  7. ncbi Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma
    Jacob A Sepmeyer
    Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 5227, USA
    J Am Acad Dermatol 56:584-7. 2007
  8. ncbi High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes
    Brian G Engelhardt
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Leuk Lymphoma 48:1728-35. 2007
  9. ncbi Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphoma
    Adriana N Schmidt
    Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Am Acad Dermatol 54:S202-5. 2006

Collaborators

  • John A Zic
  • Madan H Jagasia
  • William C Lavely
  • Dominique Delbeke
  • Bipin N Savani
  • Jacob A Sepmeyer
  • Brian G Engelhardt
  • Adriana N Schmidt
  • J Stuart Salmon
  • Stacey A Goodman
  • David S Morgan
  • Richard S Stein
  • Beth L Brogan
  • Marsha C Kinney
  • Edward R Arrowsmith
  • Katherine L Ruffner
  • Rhonda Bitting
  • Adetola A Kassim
  • Tatsuki Koyama
  • Derek W Holland
  • Stephen J Brandt
  • Wichai Chinratanalab
  • Steven Wolff
  • Paulgun Sulur
  • Friedrich G Schuening
  • Mary Ann Thompson
  • Ronald C Arildsen
  • Jason B Robbins
  • William R Macon
  • Thomas L McCurley
  • Katherine S Hamilton
  • John B Cousar
  • Judy Y Hu
  • John M Flexner

Detail Information

Publications9

  1. ncbi Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations
    J Stuart Salmon
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Clin Lymphoma Myeloma 6:273-80. 2006
    ..Therapy should be tailored to the individual clinical situation, with consideration of the underlying histology and degree of hepatic insufficiency...
  2. ncbi Natural killer-cell neoplasms
    John P Greer
    Hematology Stem Cell Transplantation, 1301 Medical Center Drive, 2665 TVC, Nashville, TN 37232, USA
    Curr Hematol Malig Rep 4:245-52. 2009
    ..Stem cell transplantation is recommended for advanced disease, owing to a poor prognosis. Novel agents, including chemotherapy, inhibitors of molecular pathways, and monoclonal antibodies, are under investigation...
  3. ncbi FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy
    William C Lavely
    Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232 2675, USA
    Int J Radiat Oncol Biol Phys 57:307-15. 2003
    ..The purpose of this study was to evaluate the accuracy of PET imaging for predicting recurrence of disease and determining fields of radiation therapy for patients with lymphoma after first-line chemotherapy...
  4. ncbi Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP)
    Madan H Jagasia
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5505, USA
    Biol Blood Marrow Transplant 15:1288-95. 2009
    ..34, 95% CI 0.14-0.8, p=.014). This study suggests that NIH classification can predict outcome after ECP for steroid refractory/dependent GVHD...
  5. ncbi Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification
    Edward R Arrowsmith
    Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5505, USA
    Leuk Lymphoma 44:241-9. 2003
    ..In conclusion, the REAL classification describes distinct PTCL entities. The IPI is the most important predictor of progression-free and OS in patients with PTCL. ALK expression may not provide prognostic information for systemic ALCL...
  6. ncbi Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series
    Beth L Brogan
    Departments of Medicine, Vanderbilt University Medical School, Nashville, Tennessee 37232-5227, USA
    J Am Acad Dermatol 49:223-8. 2003
    ..There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody...
  7. ncbi Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma
    Jacob A Sepmeyer
    Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 5227, USA
    J Am Acad Dermatol 56:584-7. 2007
    ..After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia...
  8. ncbi High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes
    Brian G Engelhardt
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Leuk Lymphoma 48:1728-35. 2007
    ..04). We have confirmed that HDT and ASCT result in long-term survival for a proportion of patients with relapsed or refractory HL. All patients, including those with primary refractory disease, benefited from HDT and ASCT...
  9. ncbi Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphoma
    Adriana N Schmidt
    Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Am Acad Dermatol 54:S202-5. 2006
    ..Future studies should aim to clarify the potential role of infectious agents, such as human T-lymphotropic virus I and II, cytomegalovirus, Epstein-Barr virus, and other environmental exposures, in the development of MF...